Royalty payment

BMG and SESAC Digital Licensing Expand Partnership for Southeast Asia and Australia/New Zealand, Administered by Mint

Retrieved on: 
월요일, 7월 19, 2021
Record labels, Expense, Intellectual property law, Patent law, Royalty payment, Music licensing, SESAC, SESAC, BMG Rights Management, SUISA

BERLIN, HONG KONG and SYDNEY, July 19, 2021 /PRNewswire/ -- SESAC Digital Licensing and BMG have expanded their partnership with new digital licensing deals for BMG's Anglo-American repertoire in Southeast Asia and Australia/New Zealand.

Key Points: 
  • BERLIN, HONG KONG and SYDNEY, July 19, 2021 /PRNewswire/ -- SESAC Digital Licensing and BMG have expanded their partnership with new digital licensing deals for BMG's Anglo-American repertoire in Southeast Asia and Australia/New Zealand.
  • On behalf of BMG, SESAC Digital Licensing will negotiate license agreements with international online service providers and with the leading local online service providers in the respective markets.
  • Mint Digital Services (Mint) is an alliance between the US music rights organization SESAC and Swiss authors' rights society SUISA.
  • BMG COO Ben Katovsky said: "With SESAC and Mint we have found an ideal partner for digital licensing and royalty administration in these rapidly growing regions.

Gulf Coast Ultra Deep Royalty Trust Announces Quarterly Cash Distribution

Retrieved on: 
금요일, 7월 16, 2021
Energy, Other Energy, Oil, Gas, Legal entities, Articles, Royalty trust, Law, Trust law, Royalty payment, Income trust

About Gulf Coast Ultra Deep Royalty Trust.

Key Points: 
  • About Gulf Coast Ultra Deep Royalty Trust.
  • The subject interests and the Trusts overriding royalty interests are described in the Trusts filings with the Securities and Exchange Commission (SEC).
  • Any differences in actual cash receipts by the Trust could affect the amount of quarterly cash distributions.
  • If you have any questions related to the Trust, please see below for contact information:
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005436/en/

Permianville Royalty Trust Announces Monthly Operational Update

Retrieved on: 
금요일, 7월 16, 2021
Energy, Professional services, Oil, Gas, Finance, Law, Legal entities, Articles, Expense, Intellectual property law, Patent law, Royalty payment, Trust law, Royalty trust, Oil and gas law in the United States, Energy

The remaining administrative advances for the prior months will be repaid with any net profits in next months net profits interest calculation.

Key Points: 
  • The remaining administrative advances for the prior months will be repaid with any net profits in next months net profits interest calculation.
  • Permianville Royalty Trust is a Delaware statutory trust formed to own a net profits interest representing the right to receive 80% of the net profits from the sale of oil and natural gas production from certain, predominantly non-operated, oil and gas properties in the states of Texas, Louisiana and New Mexico.
  • In addition, future monthly capital expenditures may exceed the average levels experienced in 2020 and prior periods.
  • Neither the Sponsor nor the Trustee intends, and neither assumes any obligation, to update any of the statements included in this press release.

DGAP-News: MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

Retrieved on: 
금요일, 7월 16, 2021
Equity securities, Financial economics, Finance, Corporate finance, Stock market, MorphoSys, Corporate law, Royalty payment, Royalty Pharma, Share capital, Stock, Common stock

The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.

Key Points: 
  • The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.
  • "We're pleased that Royalty Pharma is taking an equity position in MorphoSys as part of the long-term strategic finance partnership the two companies entered into this year," said Sung Lee, Chief Financial Officer of MorphoSys.
  • The new MorphoSys shares will be listed on the Frankfurt Stock Exchange.
  • Royalty Pharma has agreed, subject to limited exceptions, not to sell or otherwise transfer any of the new ordinary shares for a period of twelve months.

Royalty Pharma Declares Third-Quarter 2021 Dividend

Retrieved on: 
금요일, 7월 16, 2021
Royalty Pharma, Royalty payment, Dividend, Life sciences, Biotechnology, Industry economics)

NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.

Key Points: 
  • NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.
  • The dividend will be paid on September 15, 2021, to shareholders of record at the close of business on August 20, 2021.
  • Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update

Retrieved on: 
금요일, 7월 16, 2021
Expense, Intellectual property law, Patent law, Royalty payment, NicOx

The number of prescriptions1 for VYZULTA in the U.S. increased by 21% in the second quarter of 2021 compared to the second quarter of 2020.

Key Points: 
  • The number of prescriptions1 for VYZULTA in the U.S. increased by 21% in the second quarter of 2021 compared to the second quarter of 2020.
  • The number of ZERVIATE U.S. prescriptions1 increased by 712% in the second quarter of 2021 over the second quarter of 2020.
  • Net revenue2 for the second quarter of 2021 was 0.7 million (including 0.6 million of net royalty payments).
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

Retrieved on: 
목요일, 7월 15, 2021
Articles, Ethics, Ethical investment, Intellectual property law, Legorreta, Royalty Pharma, Bond, Corporate social responsibility, International Capital Market Association, Royalty payment

Royalty Pharma intends to use the net proceeds from the 2051 Notes for general corporate purposes.

Key Points: 
  • Royalty Pharma intends to use the net proceeds from the 2051 Notes for general corporate purposes.
  • Royalty Pharma has developed a Social Bond Framework aligned with the International Capital Market Associations Social Bond Principles, 2021, which are voluntary guidelines that promote transparency and integrity in the social bond market.
  • ISS ESG has reviewed that Royalty Pharmas Social Bond Framework aligns with the Social Bond Principles issued by the International Capital Markets Association.
  • We are pleased to announce the pricing of our first ever Social Bond, underscoring our strong commitment to corporate social responsibility, stated Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma.

Barrick On Course to Achieve 2021 Production Targets

Retrieved on: 
목요일, 7월 15, 2021
Expense, Intellectual property law, Patent law, Royalty payment, Barrick, Reconciliation, S&P/TSX 60, Barrick Gold

C1 cash costs per pound excludes royalties and production taxes and non-routine charges as they are not direct production costs.

Key Points: 
  • C1 cash costs per pound excludes royalties and production taxes and non-routine charges as they are not direct production costs.
  • Barrick will provide a full reconciliation of these non-GAAP financial measures when the Company reports its quarterly results on August9, 2021.
  • Barrick will provide additional discussion and analysis and other important information about its second quarter production levels and sales and associated costs when it reports actual results on August9, 2021.
  • Barrick also cautions that its 2021 guidance may be impacted by the unprecedented business and social disruption caused by the spread of Covid-19.

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

Retrieved on: 
목요일, 7월 15, 2021
Health sciences, Chess, Health, Pharmaceutical industry, Checkmate, Kuros, Royalty payment, Clinical trial, Gevokizumab

Kuros will receive an initial payment of $7 million from XOMA.

Key Points: 
  • Kuros will receive an initial payment of $7 million from XOMA.
  • In addition, Kuros retains the potential to receive up to $24 million in pre-commercial milestones from Checkmate, and is eligible to receive up to $142.5 million in sales milestones from Xoma.
  • Checkmate is conducting multiple clinical trials, including two phase 2 trials in the melanoma indication, which have already triggered two milestone payments of $2 and $4 million by Checkmate earlier this year.
  • These milestone payments together with the payment from the royalty purchase agreement announced today amount to $13 million in revenue to Kuros in 2021.

Verde Bio Holdings, Inc. Announces Opportunistic Divestiture of Assets

Retrieved on: 
목요일, 7월 15, 2021
Expense, Intellectual property law, Patent law, Royalty payment

Verde Bio Holdings will achieve approximately 84 percent profit after holding this asset for a little more than three months.

Key Points: 
  • Verde Bio Holdings will achieve approximately 84 percent profit after holding this asset for a little more than three months.
  • In addition to the profits from sale, Verde also will receive all revenue of the assets related to production from the wells from March 1, 2021, to July 31, 2021, estimated to be approximately $80,000.
  • We are going to be opportunistic for our shareholders when the situation, such as this, necessitates it.
  • About Verde Bio Holdings, Inc.: Verde Bio Holdings, Inc. (OTC: VBHI), is a U.S. Energy Company based in Frisco, Texas, engaged in the acquisition and management of Mineral and Royalty interests in lower risk, onshore oil and gas properties within the major oil and gas plays in the U.S.